Lumia, E., E. Fabiani, P. Bielli, M. Sarchi, M. Senatore, C. Fiducioso, H. Hajrullaj, C. Iannini, M. Rasicci, G. Silvestrini, N. Lelli, A. Onorato, A. Cristiano, M. Pieraccioli, F. Mallegni, F. Moretti, L. Guarnera, G. Falconi, S. Hutter, N. Nadarajah, T. Haferlach, L. Malcovati, C. Sette, and M.T. Voso. 2026. “CO36 | TGF-β Pathway Deregulation in SF3B1-Mutated Low Risk Myelodysplastic Syndrome Patients: E. Lumia1, E. Fabiani2|3, P. Bielli2, M. Sarchi4, M. Senatore2, C. Fiducioso4, H. Hajrullaj2, C. Iannini4, M. Rasicci2, G. Silvestrini2, N. Lelli1, A. Onorato2, A. Cristiano1|5, M. Pieraccioli6|7, F. Mallegni2, F. Moretti2, L. Guarnera1, G. Falconi2, S. Hutter8, N. Nadarajah8, T. Haferlach8, L. Malcovati4|9, C. Sette2, M.T. Voso2 | 1Department of Biomedicine and Prevention, PhD Program in Immunology, Molecular Medicine and Applied Biotechology, University of Tor Vergata; 2Department of Biomedicine and Prevention, University of Tor Vergata; 3UniCamillus-Saint Camillus International University of Health Sciences; 4Department of Molecular Medicine, University of Pavia; 5Operative Research Unit of Laboratory, Fondazione Policlinico Universitario Campus Bio-Medico; 6Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Hearth; 7GSTEP-Organoids Core Facility, Fondazione Policlinico Agostino Gemelli IRCCS; 8MLL Munich Leukemia Laboratory; 9Department of Hematology, Fondazione IRCCS Policlinico S. Matteo.”. Haematologica 111 (s1). Pavia, Italy. https://doi.org/10.3324/haematol.2026.s1.44.